NASDAQ: NERV

Minerva Neurosciences, Inc.

Healthcare | Biotechnology

No licensed closing price on file for NERV. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 10:13 UTC.

What Minerva Neurosciences, Inc. does

The company is a clinical-stage biopharmaceutical firm developing roluperidone, a potential treatment for negative symptoms in schizophrenia, along with other product candidates. The company is planning an additional Phase 3 clinical trial called the C19 trial in consultation with the FDA and intends to resubmit a new drug application, with funding expected from a private placement completed in October 2025. As of December 31, 2025, the company had cash and cash equivalents of $82.4 million and expects this to be sufficient for at least twelve months of operations.

Summarized from Minerva Neurosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-04
Return on equity	3.69%

Charts

Charts are in the appInteractive charts for NERV are available in Oxford Ledge.
Open NERV in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-03

2026-08-03DirectorStock Option (right to buy)Award12,147—
2026-06-05CEOEmployee Stock Option (right to buy)Award1,690,700—
2026-06-05DirectorStock Option (right to buy)Award50,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FEDERATED HERMES, INC.4,670,426$25.92M-8.7%
JANUS HENDERSON GROUP PLC4,294,259$25.87M+47614.0%
Jupiter Topco LLC4,386,027$24.32MNEW

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-08-12Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-05-30Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersDavid KupferEstimatedSEC 8-K →
2022-12-16Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does Minerva Neurosciences, Inc. do?

The company is a clinical-stage biopharmaceutical firm developing roluperidone, a potential treatment for negative symptoms in schizophrenia, along with other product candidates.

When did NERV last file with the SEC?

Minerva Neurosciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-04. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 10:13 UTC. This page is also available as JSON at /api/data?ticker=NERV and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NERV and 5,000+ tickers.

Create a free account — keep NERV

For your agent

GET /api/data?ticker=NERV

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt